REFERENCES
- Vardanian AJ, Busuttil RW, Kupiec-Weglinski JW. Molecular mediators of liver ischemia and reperfusion injury: a brief review. Mol Med. 2008;14:337–345.
- Liu A, Dirsch O, Fang H, et al. HMGB1 translocation and expression is caused by warm ischemia reperfusion injury, but not by partial hepatectomy in rats. Exp Mol Pathol. 2011;91:502–508.
- Robertson FP, Magill LJ, Wright GP, Fuller B, Davidson BR. A systematic review and meta-analysis of donor ischaemic preconditioning in liver transplantation. Transpl Int. 2016;29:1147–1154.
- Sikalias N, Karatzas T, Alexiou K, et al. Intermittent ischemic preconditioning protects against hepatic ischemia-reperfusion injury and extensive hepatectomy in steatotic rat liver. J Invest Surg. 2017; 23:1–12.
- Oltean M, Barrenäs C, Martins PN, et al. Recipient hyperbilirubinemia may reduce ischemia-reperfusion injury but fails to improve outcome in clinical liver transplantation. Gastroenterol Res Pract. 2016;2016: 6964856.
- Abenavoli L, Capasso R, Milic N, Capasso F. Milk thistle in liver diseases: past, present, future. Phytother Res. 2010;24:1423–1432.
- Lin YZ, Lu ZY, Liang XH, Li K, Peng B, Gong J. Effect of breviscapine against hepatic ischemia reperfusion injury. J Surg Res. 2016;203:268–274.
- Loguercio C, Festi D. Silybin and the liver: from basic research to clinical practice. World J Gastroenterol. 2011 May 14;17(18):2288–2301.
- Tsaroucha A, Valsami G, Kostomitsopoulos N, et al. Silibinin Effect on Fas/FasL, HMGB1 and CD45 expressions in a rat model subjected to liver ischemia-reperfusion injury (In press).
- Polachi N, Bai G, Li T, et al. Modulatory effects of silibinin in various cell signaling pathways against liver disorders and cancer—A comprehensive review. Eur J Med Chem. 2016;123:577–595.